Samples of Xebra’s crop were collected by the Dutch government’s Bureau of Medicinal Cannabis on Friday 25 March.
The company has stated the crop consisted of high THC ±22 per cent cannabis flower, and flower with balanced THC ±6 per cent and CBD± 8 per cent.
Canadian-based Xebra is endeavouring to be awarded one of two licenses, providing government guaranteed revenues for each company of a minimum of ~€70.5m to supply all pharmaceutical grade cannabis to be sold though pharmacies in the Netherlands.
Rodrigo Gallardo, president of Xebra, commented: “We have demonstrated our operational excellence, with the delivery of our first trial crop on budget and on time.
“We are extremely optimistic and confident as we now enter into the next phase of the cannabis cultivation pilot trial.”
Read more: Cannabis harvest ready to be shipped for Dutch inspection
The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters and the company has stated that the deadline for the first crop was March 29, 2022 has now been satisfied. The deadline for the second crop is September 19, 2022, and the third is March 6, 2023.
The final two license holders from the trial will be selected based on the quality of these trial crops, which will then go on to cultivate and process cannabis in the Netherlands.
Xebra must provide a detailed business plan must to Dutch authorities by November 14, 2022, with the announcement of provisional award decision by the Dutch government is scheduled for April 3, 2023, with the commencement of a Framework Agreement for commercial operations planned for May 1, 2023.
Medical cannabis in the country is the responsibility of the Office of Medicinal Cannabis (OMC), part of the Office for Health, Welfare and Sport, which has been available in the Netherlands since 2003.
[activecampaign form=31]
